Address of Corresponding Author

Pancreatology 2005;5:470-474 (DOI: 10.1159/000086551)

  Key Words

• Intraductal papillary mucinous neoplasm
• Intraperitoneal hyperthermic chemoperfusion
• Pseudomyxoma peritonei

  Abstract

We describe a case ofpseudomyxoma peritonei (PMP) successfully managed with intraperitoneal hyperthermic chemoperfusion. This case is unique due to the concurrent presence of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. The patient presented with abdominal fullness. Abdominal computed tomography revealed massive ascites, thickened peritoneum, and a cystic lesion of the pancreas. Cytological examination of ascitic fluid sample showed mucin-rich atypical cells. Endoscopic retrograde pancreatography revealed a cystic lesion with the defect probably due to mural nodule and mucin, communicating with the pancreatic duct. At exploratory laparotomy, massive ascites and multiple nodules were identified within the peritoneal cavity. No primary tumour, including mucinous neoplasm of the appendix, was found. Histopathological examination of the omentum showed mucinous adenocarcinoma in pools of mucoid material, consistent with PMP. The relation between PMP and IPMN of the pancreas was possible, but not conclusive. The patient received intraperitoneal perfusion of saline heated to 42°C containing cisplatin, etoposide, and mitomycin C, followed by 24 courses of postoperative chemotherapy with gemcitabine. The patient remains in good general condition with no signs of progression of PMP for 2 years, but with a gradual and progressive enlargement of the pancreatic cystic lesion.

Copyright © 2005 S. Karger AG, Basel and IAP

  References

1.

van Ruth S, Acherman YI, van de Vijver MJ, Hart AA, Verwaal VJ, Zoetmulder FA: Pseudomyxoma peritonei: A review of 62 cases. Eur J Surg Oncol 2003;29:682-688.

2.

Galani E, Marx GM, Steer CB, Culora G, Harper PG: Pseudomyxoma peritonei: The 'controversial' disease. Int J Gynecol Cancer 2003;13:413-418.

3.

Weaver CH: Mucocele of the appendix with pseudomucinous degeneration. Am J Surg 1937;36:523-526.

4.

D'Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC: Intraductal papillary mucinous neoplasms of the pancreas: An analysis of clinicopathologic features and outcome. Ann Surg 2004;239:400-408.

5.

Tanaka M: Intraductal papillary mucinous neoplasm of the pancreas: Diagnosis and treatment. Pancreas 2004;28:282-288.

6.

Zanelli M, Casadei R, Santini D, Gallo C, Verdirame F, La Donna M, Marrano D: Pseudomyxoma peritonei associated with intraductal papillary-mucinous neoplasm of the pancreas. Pancreas 1998;17:100-102.

7.

Gustafson KD, Karnaze GC, Hattery RR, Scheithauer BW: Pseudomyxoma peritonei associated with mucinous adenocarcinoma of the pancreas: CT findings and CT-guided biopsy. J Comput Assist Tomogr 1984;8:335-338.

8.

Chejfec G, Rieker WJ, Jabloknow VR, Gould VE: Pseudomyxoma peritonei associated with colloid carcinoma of the pancreas. Gastroenterology 1986;90:202-205.

9.

Shen DH, Ng TY, Khoo US, Xue WC, Cheung AN: Pseudomyxoma peritonei - A heterogeneous disease. Int J Gynaecol Obstet 1998;62:173-182.

10.

Mitsuhashi T, Murata N, Sobajima J, Okada N, Suzuki T, Ishida H, Hashimoto D, Miura I, Itoyama S: A case of pseudomyxoma peritonei with a pancreatic cancer treated by the intraperitoneal administration of cisplatinum (in Japanese). Gan To Kagaku Ryoho 2001;28:1670-1673.

11.

Kawai M, Uchiyama K, Tani M, Onishi H, Kinoshita H, Ueno M, Hama T, Yamaue H: Clinicopathological features of malignant intraductal papillary mucinous tumors of the pancreas: The differential diagnosis from benign entities. Arch Surg 2004;139:188-192.

12.

Yasuda H, Takada T, Amano H, Yoshida M: Surgery for mucin-producing pancreatic tumor. Hepatogastroenterology 1998;45:2009-2015.

13.

Hirooka Y, Goto H, Itoh A, Hashimoto S, Niwa K, Ishikawa H, Okada N, Itoh T, Kawashima H: Case of intraductal papillary mucinous tumor in which endosonography-guided fine-needle aspiration biopsy caused dissemination. J Gastroenterol Hepatol 2003;18:1323-1324.

14.

Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C, Kusamura S: Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): A strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004;11:393-398.

15.

Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001;27:239-243.

16.

Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, Dalton RR, Ettinghausen SE, Jacquet P, Jelinek J, Koslowe P, Kurman RJ, Shmookler B, Stephens AD, Steves MA, Stuart OA, White S, Zahn CM, Zoetmulder FA: Pseudomyxoma peritonei syndrome. Adv Surg 1996;30:233-280.

17.

Horiki N, Maruyama M, Fujita Y, Suzuki Y, Tanaka T, Shimomura M, Tanigawa K, Sasaki H, Fujiwara M, Suzuki K, Imoto I, Adachi Y: Gemcitabine treatment of pancreatic cancer peritonitis (in Japanese). Nippon Shokakibyo Gakkai Zasshi 2003;100:73-78.

18.

Li D, Xie K, Wolff R, Abbruzzese JL: Pancreatic cancer. Lancet 2004;363:1049-1057.

19.

Koda K, Nakazawa O, Terada S, Kure T, Morita K, Hirayama M, Fukushi A, Terui T, Yoshizaki N, Takahashi H: Intraperitoneal (IP) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: Clinical evaluation and pharmacokinetics (in Japanese). Gan No Rinsho 1988;34:191-195.

  Author Contacts

Yohei Mizuta, MD
Second Department of Internal Medicine
Nagasaki University School of Medicine
1-7-1, Sakamoto, Nagasaki 852-8501 (Japan)
Tel. +81 95 849 7273, Fax +81 95 849 7285, E-Mail ymizuta@net.nagasaki-u.ac.jp

  Article Information

Published online: June 27, 2005
Number of Print Pages : 5
Number of Figures : 4, Number of Tables : 1, Number of References : 19

  Publication Details

Pancreatology

Vol. 5, No. 4-5, Year 2005 (Cover Date: 2005)

Journal Editor: Urrutia, R. (Rochester, Minn.)
ISSN: 1424-3903 (print), 1424-3911 (Online)

For additional information: http://www.karger.com/pan

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.